Global Urinary Tract Infection Therapeutics Market Growing at CAGR of 3.5% by 2023 – Top players: PFIZER LIMITED, BOEHRINGER INGELHEIM, BAYER AG, GLAXOSMITHKLINE, NOVARTIS AG, F. HOFFMANN-LA ROCHE, JOHNSON & JOHNSON, ASTRAZENECA, CIPLA

The global urinary tract infection therapeutics market is expected to register a CAGR of 3.5% during the forecast period 2018 to 2023. North America dominates the market due to high urinary tract infection (UTI) detection, along with increasing prevalence of diabetes in the region.

Detailed Sample Copy of Updated Analysis @ https://marketprognosis.com/sample-request/16828
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Increasing Prevalence of Diabetes and Kidney Stones
According to World Health Organization (WHO), in 1980, there were 108 million people suffering from diabetes; this number increased to 422 million in 2014, while the prevalence of diabetes in adults increased from 4.7% in 1980 to 8.5% in 2014. This trend of increment in the prevalence rate of diabetes among adults is expected to continue during the forecast period. Therefore, with increasing prevalence, the number of UTI increases, and thus, the high demand for drugs. Hence, increasing prevalence of diabetes worldwide is expected to act as a major driver for the global urinary tract infection therapeutics market.
In addition, launch of combination drugs, which are more effective, and increasing geriatric population are also expected to boost the growth of the urinary tract infection therapeutics market.

Key Developments in the Market
• August 2017: FDA approved Vabomere for adults. Vabomere is an antibacterial drug, which is used for the treatment of complicated urinary tract infections (cUTI) and pyelonephritis (a type of kidney infection caused by specific bacteria). Vabomere contains meropenem and vaborbactam.
• December 2017: The F.D.A accepted the review of NDA (New Drug Application) submitted by Achaogen for plazomicin to treat cUTI, including pyelonephritis and bloodstream infections (BSI), and has set a target action date under Prescription Drug User Fee Act (PDUFA) in June, 2018.

Major Players:
PFIZER LIMITED, BOEHRINGER INGELHEIM, BAYER AG, GLAXOSMITHKLINE PLC, NOVARTIS AG, F. HOFFMANN-LA ROCHE LTD, JOHNSON & JOHNSON, ASTRAZENECA, CIPLA INC., and MERLION PHARMA, amongst others.

Request Discount on this report @ https://marketprognosis.com/discount-request/16828
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

Adverse Effects Associated with the Use of Medication
According to Centers for Education & Research on Therapeutics, over 2 million cases of Adverse Drug Reactions (ADRs) are reported every year, out of which, there are approximately 100,000 deaths. According to FDA, it is also estimated that each year over 350,000 ADRs occur in the US nursing homes alone. With such increasing cases of ADRs being reported all over the world, there is averseness among the population across for the adoption of drugs, which is acting as a major restraint for the urinary tract infection therapeutics market.
Additionally, lack of awareness about the prevalence of UTI in developing and underdeveloped nations is restraining the growth of the market.

North America to Dominate the Market
The urinary tract infection therapeutics market is segmented by drug type, indication type, and geography. By geography, it is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and South America.
North America dominates the urinary tract infection therapeutics market due to high UTI detection, along with increasing diabetes prevalence in the region. Europe is also expected to boost the UTI therapeutics market, owing to increased accessibility to healthcare facilities, along with high UTI prevalence among the population.

Enquiry Before Buying@ https://marketprognosis.com/enquiry/16828
Note: “If this link doesn’t work in Internet Explorer, kindly try copy pasting it in other browsers”.

About Market Prognosis
We at Market Prognosis believe in giving a crystal clear view of market dynamics for achieving success in today’s complex and competitive marketplace through our quantitative & qualitative research methods.
We help our clients identify the best market insights and analysis required for their business thus enabling them to take strategic and intelligent decision.
We believe in delivering actionable insights for your business growth and success.

Contact us:
ProgMarkPvt Ltd,
Thane - 421501
India.
Contact No: +1 973 241 5193
Email: sales@marketprognosis.com

This release was published on openPR.